Can a Weekly Shot Curb Your Alcohol Cravings? New Semaglutide Trial Offers an Answer
FODMAP Everyday, syndicated on Yahoo, reports on a phase 2 Lancet trial of 108 adults with both alcohol use disorder and obesity. All received ten cognitive behavioral therapy sessions, plus either weekly semaglutide titrated to 2.4 mg or a placebo. Over 26 weeks, heavy drinking days fell 41.1% with semaglutide, 13.7 percentage points beyond placebo. Researchers say larger trials must confirm the results.
Why it matters: Relevant to Maryland adults living with both obesity and alcohol use disorder, and to clinicians who prescribe GLP-1 medications or refer patients for addiction care.
A summary of another publisher's reporting, written with AI and checked automatically against the story. The reporting belongs to health.yahoo.com. October 8, 2026.